OpenNashEarnings

Becton Dickinson (BDX) · Medical Devices

Becton Dickinson Q4 FY2026 earnings: summary, key numbers & outlook

Results filed 5 Nov 2026 · Quarter ended 29 Sep 2026

Slides (29 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

BD signed a U.S. government manufacturing partnership with $19 billion of planned investment and Section 232 tariff relief, while launching new vascular and tissue-regeneration products as New BD.

BD finished its transformation into a four-segment MedTech company after spinning off its Biosciences and Diagnostic Solutions business into Waters in February. Growth was led by Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa. Interventional grew fastest of the four segments. Connected Care lagged as Alaris infusion pump capital sales fell. BD also won U.S. launch clearance for new vascular and hernia products.

Management is steering toward faster innovation, commercial investment in growth platforms and BD Excellence productivity work, and plans to detail the strategy at its December 10 Investor Day. The U.S. Government partnership brings a $19 billion investment plan and conditional tariff relief. The tension is that fiscal 2027 growth is guided to low single digits, with about 200 bps of drag from Alaris capital, so growth platforms must offset a weaker pump cycle.

Slides & documents

Open the slide deck (PDF, 29 pages) ↗

Becton Dickinson Q4 FY2026 slide deck, page 1Becton Dickinson Q4 FY2026 slide deck, page 2Becton Dickinson Q4 FY2026 slide deck, page 3Becton Dickinson Q4 FY2026 slide deck, page 4Becton Dickinson Q4 FY2026 slide deck, page 5Becton Dickinson Q4 FY2026 slide deck, page 6

Showing the first 6 of 29 pages.

SEC filing

Key numbers

Q4 revenue · GAAP
$5.3 billion

increased 5.4% as reported, 5.6% FXN

Q4 diluted EPS · GAAP
$2.52

up 110.0% from a year ago

Q4 adjusted diluted EPS · non-GAAP
$4.15

up 27.3% from a year ago

FY26 cash from continuing operations · GAAP
$3.6 billion

increased 30.0%

FY26 free cash flow · non-GAAP
$2.9 billion

increased 42.5%

Segment or metricValueChange
Medical Essentials$1.8Bup 5.9% reported, 5.9% FXN
Connected Care$1.3Bup 1.6% reported, 2.1% FXN
BioPharma Systems$748.0Mup 6.5% reported, 7.0% FXN
Interventional$1.5Bup 7.6% reported, 7.6% FXN
Where each number comes from
  • Q4 revenue: “Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN”
  • Q4 diluted EPS: “Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively”
  • Q4 adjusted diluted EPS: “Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively”
  • FY26 cash from continuing operations: “FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion”
  • FY26 free cash flow: “FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion”
  • Medical Essentials: “Medical Essentials2 | $1,786 | $1,686 | 5.9% | 5.9%”
  • Connected Care: “Connected Care2 | $1,269 | $1,250 | 1.6% | 2.1%”
  • BioPharma Systems: “BioPharma Systems2 | $748 | $702 | 6.5% | 7.0%”
  • Interventional: “Interventional2 | $1,472 | $1,367 | 7.6% | 7.6%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

XBRL figures for this quarter arrive with the 10-Q or 10-K; the numbers above are from the press release.

Outlook

MetricPeriodOutlook
Adjusted diluted EPSfiscal 2027$13.10 to $13.30

Key takeaways

  1. U.S. government partnership anchors domestic manufacturing push

    BD intends to invest $19 billion in the U.S. over several years, with $3 billion directed toward manufacturing expansion. The agreement also provides relief from future Section 232 tariffs on covered products, subject to final scope and BD meeting agreed milestones.

  2. Interventional launches broaden BD's addressable markets

    BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27, entering a $2B global venous market, and received 510(k) clearance for Phasix ST Parastomal Hernia Mesh. Revello covered stent iliac data from the AGILITY trial were positive.

  3. Advanced Patient Monitoring is a standout growth engine

    APM grew 17.3% FXN in Q4, led by HemoSphere Alta and Acumen IQ products. BD credits sales force investment and says HemoSphere Alta had strong uptake.

  4. Alaris share gains coexist with a capital headwind

    BD Alaris gained additional share in Q4, and Medication Management Solutions grew mid-single digits excluding Alaris. Even so, FY27 guidance carries about a 200 bps Alaris capital headwind, and Connected Care grew only 2.1% FXN.

  5. BioPharma Systems rides GLP-1 demand in biologic delivery

    BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength and healthy utilization. A moderating vaccine headwind partly offset it, and BD says it is expanding its position in next-generation biologic drug delivery.

Charts

Revenue$5.0B+5.4% y/yQ3 FY26
Q4 FY24: $5.4B (worked out from the annual figure)Q4 24$5.4BQ1 FY25: $5.2BQ1 25$5.2BQ2 FY25: $4.5BQ2 25$4.5BQ3 FY25: $4.7BQ3 25$4.7BQ4 FY25: $8.3B (worked out from the annual figure)Q4 25$8.3BQ1 FY26: $5.3BQ1 26$5.3BQ2 FY26: $4.7BQ2 26$4.7BQ3 FY26: $5.0BQ3 26$5.0B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$5.4B *
Q1 FY25$5.2B
Q2 FY25$4.5B
Q3 FY25$4.7B
Q4 FY25$8.3B *
Q1 FY26$5.3B
Q2 FY26$4.7B
Q3 FY26$5.0B
Diluted EPS (GAAP)$1.37−31.5% y/yQ3 FY26
Q1 FY25: $1.04Q1 25$1.04Q2 FY25: $1.07Q2 25$1.07Q3 FY25: $2.00Q3 25$2.00Q1 FY26: $1.34Q1 26$1.34Q2 FY26: -$1.11Q2 26-$1.11Q3 FY26: $1.37Q3 26$1.37
Data
Q1 FY25$1.04
Q2 FY25$1.07
Q3 FY25$2.00
Q1 FY26$1.34
Q2 FY26-$1.11
Q3 FY26$1.37

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin13.3%−2.3 pts y/yQ3 FY26
Q4 FY24: 11.4%Q4 2411.4%Q1 FY25: 8.8%Q1 258.8%Q2 FY25: 8.5%Q2 258.5%Q3 FY25: 15.6%Q3 2515.6%Q4 FY25: 14.1%Q4 2514.1%Q1 FY26: 10.5%Q1 2610.5%Q2 FY26: 2.0%Q2 262.0%Q3 FY26: 13.3%Q3 2613.3%
Data
Q4 FY2411.4%
Q1 FY258.8%
Q2 FY258.5%
Q3 FY2515.6%
Q4 FY2514.1%
Q1 FY2610.5%
Q2 FY262.0%
Q3 FY2613.3%
Free cash flow$549.0M−6.6% y/yQ1 FY26
Q1 FY25: $588.0MQ1 25$588.0MQ1 FY26: $549.0MQ1 26$549.0M
Data
Q1 FY25$588.0M
Q1 FY26$549.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is BD's U.S. Government partnership?

BD intends to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion, to strengthen domestic supply chains for essential medical consumables. It also provides relief from future Section 232 tariffs on covered products, subject to final scope and milestones.

Which BD products drove growth this quarter?

Advanced Patient Monitoring grew 17.3% FXN, led by HemoSphere Alta and Acumen IQ. PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa also grew at double-digit rates.

What new products did BD launch or win clearance for?

BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27 after an EU launch in Q3 FY26. It received 510(k) clearance for Phasix ST Parastomal Hernia Mesh, with a U.S. launch expected in 1H FY27.

How is BD positioned in GLP-1 and biologic drug delivery?

BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength. Management says it is expanding its position in next-generation biologic drug delivery.

What does BD expect for fiscal 2027?

BD guides to low single-digit FXN revenue growth, including about a 200 bps Alaris capital headwind, and adjusted EPS of $13.10 to $13.30. Q1 revenue growth is expected at the low end of the range, and BD will hold an Investor Day on December 10.

Call recording

Call recording on YouTube ↗. Official replay ↗.